Skip Nav Destination
Issues
1 February 2024
-
Cover Image
Cover Image
The cover image is adapted from Fig. 4 in the article, “Increase in the Life Expectancy of Cancer Patients in the United States,” by Devasia and colleagues. Cancer is becoming more of a chronic disease due to improvements in treatment and early detection for multiple cancer sites. To gain insight on increased life expectancy due to these improvements Devasia and colleagues quantified trends in the loss in expectation of life (LEL) due to a cancer diagnosis for six cancer sites from 1975 through 2018. The authors focused on patients diagnosed with female breast cancer, chronic myeloid leukemia (CML), colon and rectum cancer, diffuse large B-cell lymphoma (DLBCL), lung cancer, or melanoma between 1975 and 2018 from nine SEER cancer registries. Over 2 million patients were diagnosed with one of the six cancers between 1975 and 2018. Large increases in life expectancy were observed between 1990 and 2010 for female breast, DLBCL, and CML. Patients with colon and rectum cancer and melanoma had more gradual improvements in life expectancy. Lung cancer LEL only began decreasing after 2005. Figure 4 shows the LEL by cancer site. Increases in life expectancy corresponded with decreases in LEL for cancer patients. The reported gains in life expectancy largely correspond to progress in the screening, management, and treatment of these six cancers since 1975. LEL provides an important public health perspective on how improvements in treatment and early detection and their impacts on survival translate into changes in cancer patients' life expectancy. For more information, see the article beginning on page 196. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1055-9965
EISSN 1538-7755
Highlights
Commentary
In the Spotlight
Cancer Surveillance Research
Research Articles
Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
Po-Hong Liu; Rasmi G. Nair; Celette Sugg Skinner; Caitlin C. Murphy; Eric J. Kim; Cynthia Ortiz; Lei Wang; Ellen Hu; Jacquelyn M. Lykken; Theodore R. Levin; Beverly B. Green; Erin E. Hahn; Noel Santini; Ethan A. Halm
Genetic Factors and Long-term Treatment-Related Neurocognitive Deficits, Anxiety, and Depression in Childhood Leukemia Survivors: An Exome-Wide Association Study
Kateryna Petrykey; Sarah Lippé; Serge Sultan; Philippe Robaey; Simon Drouin; Laurence Affret-Bertout; Patrick Beaulieu; Pascal St-Onge; Jessica L. Baedke; Yutaka Yasui; Melissa M. Hudson; Caroline Laverdière; Daniel Sinnett; Maja Krajinovic
Genetic and Environmental Causes of Variation in an Automated Breast Cancer Risk Factor Based on Mammographic Textures
Zhoufeng Ye; Gillian S. Dite; Tuong L. Nguyen; Robert J. MacInnis; Daniel F. Schmidt; Enes Makalic; Osamah M. Al-Qershi; Tu Nguyen-Dumont; Benjamin Goudey; Jennifer Stone; James G. Dowty; Graham G. Giles; Melissa C. Southey; John L. Hopper; Shuai Li
Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016
Sarah J. Lord; Benjamin Daniels; Dianne L. O'Connell; Belinda E. Kiely; Jane Beith; Andrea L. Smith; Sallie-Anne Pearson; Kim-Lin Chiew; Max K. Bulsara; Nehmat Houssami
Null Results in Brief
ASPO Report
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.